Biotech · Private company · Seattle, WA, US
HDT Bio
Track this companyFree. Adds HDT Bio to your Dealase workspace and tells you when its record changes.
Clinical trials21 recruiting or active
Pipeline programs4From trials and the company's site
Disclosed deals0None found yet
Cash runwayNot availablePrivate: no SEC financials
Pipeline4
- 10 ug HDT 321Phase 1 · VaccineClinicalTrials.gov · fetched Nov 12, 2026
- 25ug HDT-321Phase 1 · VaccineClinicalTrials.gov · fetched Nov 12, 2026
- 50ug HDT-321Phase 1 · VaccineClinicalTrials.gov · fetched Nov 12, 2026
- HDT-301Phase 1 · SARS-CoV2 InfectionClinicalTrials.gov · fetched Nov 12, 2026
Clinical trials2
- Safety and Immunogenicity of a Self-Amplifying RNA Vaccine Against Crimean-Congo Hemorrhagic FeverPHASE1 · RECRUITING · started Jul 10, 2025ClinicalTrials.gov NCT06799013 · fetched Nov 12, 2026
- Safety and Immunogenicity of HDT-301 Targeting a SARS-CoV-2 Variant Spike ProteinPHASE1 · COMPLETED · started Jan 24, 2022ClinicalTrials.gov NCT05132907 · fetched Nov 12, 2026
NIH awards6
- Immunological mechanism of muscle-localizing self-replicating RNA vaccinesFiscal year 2026 · $1.1MNIH RePORTER 5R01AI180195-03 · fetched Nov 12, 2026
- Immunological mechanism of muscle-localizing self-replicating RNA vaccinesFiscal year 2025 · $1.1MNIH RePORTER 5R01AI180195-02 · fetched Nov 12, 2026
- Engineering the Immune Response of a Self-replicating and Adjuvanting RNA HIV-1VaccineFiscal year 2025 · $981.7KNIH RePORTER 5R33AI161811-05 · fetched Nov 12, 2026
- Immunological mechanism of muscle-localizing self-replicating RNA vaccinesFiscal year 2024 · $1.1MNIH RePORTER 1R01AI180195-01 · fetched Nov 12, 2026
- Engineering the Immune Response of a Self-replicating and Adjuvanting RNA HIV-1VaccineFiscal year 2024 · $981.9KNIH RePORTER 4R33AI161811-04 · fetched Nov 12, 2026
- RNA Vaccine Innovations for TB: Targeting the MucosaFiscal year 2024 · $543.3KNIH RePORTER 5R61AI169207-03 · fetched Nov 12, 2026